Is Altimmune Stock a Good Investment?
Altimmune Investment Advice | ALT |
- Examine Altimmune's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Altimmune's leadership team and their track record. Good management can help Altimmune navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Altimmune's business and its evolving consumer preferences.
- Compare Altimmune's performance and market position to its competitors. Analyze how Altimmune is positioned in terms of product offerings, innovation, and market share.
- Check if Altimmune pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Altimmune's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Altimmune stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Altimmune is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Altimmune Stock
Researching Altimmune's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 54.0% of the company shares are held by institutions such as insurance companies. The book value of Altimmune was presently reported as 1.71. The company recorded a loss per share of 1.34. Altimmune last dividend was issued on the 20th of January 2017. The entity had 1:30 split on the 14th of September 2018.
To determine if Altimmune is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Altimmune's research are outlined below:
| Altimmune generated a negative expected return over the last 90 days | |
| Altimmune has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 20 K. Reported Net Loss for the year was (95.06 M) with loss before taxes, overhead, and interest of (82.21 M). | |
| Altimmune has about 184.76 M in cash with (79.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81. | |
| Altimmune has a poor financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Directed Energy Weapons Market Valuation to Reach US 32.53 Billion By 2033 Astute Analytica |
Altimmune Quarterly Accounts Payable |
|
Altimmune uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Altimmune. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Altimmune's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Altimmune's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Altimmune's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-11 | 2022-06-30 | -0.47 | -0.42 | 0.05 | 10 | ||
2020-05-13 | 2020-03-31 | -0.32 | -0.26 | 0.06 | 18 | ||
2023-02-28 | 2022-12-31 | -0.5 | -0.43 | 0.07 | 14 | ||
2023-05-11 | 2023-03-31 | -0.48 | -0.4 | 0.08 | 16 | ||
2022-03-15 | 2021-12-31 | -0.65 | -0.57 | 0.08 | 12 | ||
2021-05-17 | 2021-03-31 | -0.47 | -0.38 | 0.09 | 19 | ||
2024-03-27 | 2023-12-31 | -0.43 | -0.33 | 0.1 | 23 | ||
2021-08-10 | 2021-06-30 | -0.5 | -0.6 | -0.1 | 20 |
Altimmune Target Price Consensus
Altimmune target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Altimmune's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Altimmune analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Altimmune stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Altimmune, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAltimmune Target Price Projection
Altimmune's current and average target prices are 5.81 and 22.86, respectively. The current price of Altimmune is the price at which Altimmune is currently trading. On the other hand, Altimmune's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Altimmune Target Price
Altimmune Analyst Ratings
Altimmune's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Altimmune stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Altimmune's financials, market performance, and future outlook by experienced professionals. Altimmune's historical ratings below, therefore, can serve as a valuable tool for investors.Know Altimmune's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Altimmune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Altimmune backward and forwards among themselves. Altimmune's institutional investor refers to the entity that pools money to purchase Altimmune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-12-31 | 665.9 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 633.4 K | Two Sigma Investments Llc | 2024-12-31 | 605.3 K | Goldman Sachs Group Inc | 2024-12-31 | 526.2 K | Susquehanna International Group, Llp | 2024-12-31 | 500.9 K | D. E. Shaw & Co Lp | 2024-12-31 | 459.8 K | Ensign Peak Advisors Inc | 2024-12-31 | 455 K | Schroder Investment Management Group | 2024-12-31 | 428.3 K | Millennium Management Llc | 2024-12-31 | 345.6 K | Blackrock Inc | 2024-12-31 | 6.2 M | Ameriprise Financial Inc | 2024-12-31 | 5.3 M |
Altimmune's market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 459.77 M.Market Cap |
|
Altimmune's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.68) | (0.72) | |
| Return On Capital Employed | (0.80) | (0.84) | |
| Return On Assets | (0.68) | (0.72) | |
| Return On Equity | (0.77) | (0.81) |
Determining Altimmune's profitability involves analyzing its financial statements and using various financial metrics to determine if Altimmune is a good buy. For example, gross profit margin measures Altimmune's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Altimmune's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Altimmune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Altimmune. Check Altimmune's Beneish M Score to see the likelihood of Altimmune's management manipulating its earnings.
Evaluate Altimmune's management efficiency
Altimmune has Return on Asset of (0.3685) % which means that on every $100 spent on assets, it lost $0.3685. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.5986) %, meaning that it generated no profit with money invested by stockholders. Altimmune's management efficiency ratios could be used to measure how well Altimmune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.72 in 2025. Return On Capital Employed is likely to drop to -0.84 in 2025. At this time, Altimmune's Total Current Liabilities is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 3.3 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 101.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.74 | 1.65 | |
| Tangible Book Value Per Share | 1.74 | 1.65 | |
| Enterprise Value Over EBITDA | (5.03) | (4.78) | |
| Price Book Value Ratio | 4.14 | 4.35 | |
| Enterprise Value Multiple | (5.03) | (4.78) | |
| Price Fair Value | 4.14 | 4.35 | |
| Enterprise Value | 476.7 M | 500.5 M |
The decision-making processes within Altimmune are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 0.855 |
Basic technical analysis of Altimmune Stock
As of the 20th of March, Altimmune shows the Risk Adjusted Performance of (0.13), standard deviation of 4.15, and Mean Deviation of 3.13. Altimmune technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Altimmune's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Altimmune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Altimmune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Altimmune insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Roberts M Scot over a month ago Acquisition by Roberts M Scot of 7775 shares of Altimmune subject to Rule 16b-3 | ||
Roberts M Scot over a month ago Acquisition by Roberts M Scot of 6166 shares of Altimmune subject to Rule 16b-3 | ||
Vipin Garg over a month ago Acquisition by Vipin Garg of 164800 shares of Altimmune subject to Rule 16b-3 | ||
Vipin Garg over a month ago Acquisition by Vipin Garg of 42050 shares of Altimmune subject to Rule 16b-3 | ||
Schafer Klaus over six months ago Acquisition by Schafer Klaus of 26100 shares of Altimmune at 2.5 subject to Rule 16b-3 | ||
Harris Matthew Scott over six months ago Acquisition by Harris Matthew Scott of 58400 shares of Altimmune subject to Rule 16b-3 | ||
Roberts M Scot over six months ago Acquisition by Roberts M Scot of 1436 shares of Altimmune at 10.2085 subject to Rule 16b-3 |
Altimmune's Outstanding Corporate Bonds
Altimmune issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Altimmune uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Altimmune bonds can be classified according to their maturity, which is the date when Altimmune has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Altice France 8125 Corp BondUS02156LAA98 | View | |
| ALTICE FRANCE S Corp BondUS02156LAE11 | View | |
| Altice France 55 Corp BondUS02156LAC54 | View | |
| US02156LAH42 Corp BondUS02156LAH42 | View | |
| US02156LAF85 Corp BondUS02156LAF85 | View | |
| Altice Europe 5 Corp BondUS02154CAF05 | View | |
| US02154CAH60 Corp BondUS02154CAH60 | View | |
| Altice Europe 105 Corp BondUS02156TAB08 | View |
Understand Altimmune's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Altimmune's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 3.13 | |||
| Coefficient Of Variation | (657.22) | |||
| Standard Deviation | 4.15 | |||
| Variance | 17.2 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 18.01 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 5.62 | |||
| Skewness | 0.5293 | |||
| Kurtosis | 1.35 |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 3.13 | |||
| Coefficient Of Variation | (657.22) | |||
| Standard Deviation | 4.15 | |||
| Variance | 17.2 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 18.01 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 5.62 | |||
| Skewness | 0.5293 | |||
| Kurtosis | 1.35 |
Consider Altimmune's intraday indicators
Altimmune intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Altimmune stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Altimmune Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 26th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Altimmune Stock media impact
Far too much social signal, news, headlines, and media speculation about Altimmune that are available to investors today. That information is available publicly through Altimmune media outlets and privately through word of mouth or via Altimmune internal channels. However, regardless of the origin, that massive amount of Altimmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Altimmune news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Altimmune relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Altimmune's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Altimmune alpha.
Altimmune Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Altimmune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Altimmune Maximum Pain Price Across June 20th 2025 Option Contracts
Altimmune's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Altimmune close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Altimmune's options.
Altimmune Corporate Management
| Scot Roberts | Chief Scientific Officer | Profile | |
| Tony BS | Vice Management | Profile | |
| Richard MBA | Chief Officer | Profile | |
| Kent BSEE | Co Controller | Profile | |
| Andrew MS | Corporate Controller | Profile | |
| Bertrand Georges | Chief Officer | Profile |
Already Invested in Altimmune?
The danger of trading Altimmune is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Altimmune is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Altimmune. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Altimmune is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.